Our Corporate team, led by partners Dan Kramer and Roberta Bozzoli, and assisted by senior associates Ebru Davidson and Madeleine Kulakauskas, acted for QBiotics Limited, an Australian biotechnology company of approximately 1400 mostly retail shareholders. The company sought to raise AUD $12.5 million by way of prospectus which was oversubscribed.
QBiotics Limited is developing a pipeline of promising drugs in the area of cancer and wound healing for both the human and veterinary markets. Its lead drug, EBC-46, targets solid tumours and is currently in late pre-clinical development in preparation for a Human Clinical Phase I/II trial with the USA’s FDA. EBC-46 is also in late stage development for the veterinary market through the USA’s FDA-CVM.